Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

Active:	No
Cancer Type:	Unknown Primary	NCT ID:	NCT03327857
Trial Phases:	Phase I	Protocol IDs:	2017.002.01 (primary) NCI-2018-01343
Eligibility:	12 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AltruBio Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03327857

Summary

A Phase I study to establish the pharmacokinetics, pharmacodynamics, safety and efficacy
profiles of Neihulizumab in patients with steroid-refractory or treatment refractory
acute graft-versus-host disease (SR/TR-aGVHD)

Objectives

Neihulizumab (ALTB-168) is an immune checkpoint agonist antibody that regulates T cell
homeostasis. The unique mechanism of action provides a natural regulation of T cell
homeostasis that induces cell death preferentially in late-stage activated T cells
without affecting resting T cells and early-activated T cells. Because pathogenic T cells
underlying the inflammatory conditions are usually in late-stage activated state,
eliminating this population of cells can potentially result in controlling autoimmune
inflammation of T cell associated diseases, such as GvHD.

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.